This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PGX-510

Perlegen Sciences, Inc.

Drug Names(s): Netoglitazone, MCC-555, RWJ-241947

Description: PGX-510 is a thiazolidinedione, which acts as either a full or partial PPAR-gamma agonist, or antagonist, in a cell type specific manner.

Deal Structure: In April 2005, Perlegen entered into an exclusive license agreement with Mitsubishi Pharma Corporation, or Mitsubishi, for the use of PGX-510 and certain other compounds in all indications in humans throughout the world, except for certain territories retained by Mitsubishi in Asia. The license is exclusive for the duration of the royalty obligations. The royalty obligations expire on a country-by-country basis after a period of years following launch of the product or the last to expire of the licensed patents. After all the royalty obligations have expired, each partys license will continue on a non-exclusive basis.

Subject to the terms and conditions of the agreement, Mitsubishi granted to Perlegen an exclusive license to use netoglitazone and certain related intellectual property outside Asia. Perlegen granted to Mitsubishi an exclusive license in Asia to certain of its future genetic diagnostic intellectual property for use with netoglitazone. Pursuant to the agreement,...See full deal structure in Biomedtracker


PGX-510 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug